Cancer and inflammation: implications for pharmacology and therapeutics

F Balkwill; A Mantovani

doi:10.1038/clpt.2009.312

Cancer and inflammation: implications for pharmacology and therapeutics

Clin Pharmacol Ther. 2010 Apr;87(4):401-6. doi: 10.1038/clpt.2009.312. Epub 2010 Mar 3.

Authors

F Balkwill¹, A Mantovani

Affiliation

¹ Centre for Cancer and Inflammation, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. f.balkwill@qmul.ac.uk

PMID: 20200512
DOI: 10.1038/clpt.2009.312

Abstract

Smoldering, nonresolving inflammation is a component of the tumor microenvironment. The linkage between inflammation and cancer, first perceived in the nineteenth century, is now part of an accepted paradigm of carcinogenesis.

Publication types

Review

MeSH terms

Animals
Anti-Inflammatory Agents / pharmacology
Clinical Trials as Topic
Cytokines / metabolism
Drug Delivery Systems*
Drug Evaluation, Preclinical
Humans
Inflammation / complications*
Inflammation / drug therapy
Inflammation / physiopathology
Neoplasms / etiology*
Neoplasms / physiopathology
Neoplasms / prevention & control

Substances

Anti-Inflammatory Agents
Cytokines